Use of bisphosphonates (Bis) combined with sunitinib (Su) to improve the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC)

被引：0
|
作者：
Peer, Avivit
Ish-Shalom, Maya
Hammers, Hans J.
Eisenberger, Mario A.
Sinibaldi, Victoria J.
Pili, Roberto
Maimon, Natalie
Gottfried, Maya
Hayat, Henry
Kovel, Svetlana
Sella, Avishay
Neumann, Avivit
Boursi, Ben
Berger, Raanan
Carducci, Michael Anthony
Keizman, Daniel
机构：
[1] Rambam Hlth Care Campus, Haifa, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Meir Med Ctr, Genitourinary Oncol Serv,Div Oncol, Kefar Sava, Israel
[3] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[5] Wolfson Med Ctr, Dept Oncol, Holon, Israel
[6] Asaf Harofe Med Ctr, Dept Oncol, Zerifin, Israel
[7] Assaf Harofeh Med Ctr, IL-70300 Zerifin, Israel
[8] Rambam Med Ctr, Dept Oncol, Haifa, Israel
[9] Chaim Sheba Med Ctr, Ramat Gan, Israel
[10] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel
[11] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[12] Sidney Kimmel Comprehens Canc, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4619
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Low dose interferon-α2b (IFN) + thalidomide (T) in patients (pts) with previously untreated renal cell cancer (RCC).: Improvement in progression-free survival (PFS) but not quality of life (QoL) or overall survival (OS).: A phase III study of the Eastern Cooperative Oncology Group (E2898).
    Gordon, MS
    Manola, J
    Fairclough, D
    Cella, D
    Richardson, R
    Sosman, J
    Kasimis, B
    Dutcher, JP
    Wilding, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 386S - 386S
  • [42] Avelumab plus axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial
    Motzer, Robert J.
    Penkov, Konstantin
    Uemura, Hirotsugu
    Campbell, Matthew T.
    Kollmannsberger, Christian K.
    Lee, Jae-Lyun
    Venugopal, Balaji
    Van Den Eertwegh, Alfonsus
    Negrier, Sylvie
    Gurney, Howard
    Albiges, Laurence
    Berger, Raanan
    Haanen, John
    Rini, Brian I.
    Larkin, James
    Schmidinger, Manuela
    Sandner, Robin
    Wang, Jing
    Di Pietro, Alessandra
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database.
    Shi, Qian
    De Gramont, Aimery
    Buyse, Marc E.
    Grothey, Axel
    Schmoll, Hans-Joachim
    Seymour, Matthew T.
    Adams, Richard A.
    Saltz, Leonard
    Goldberg, Richard M.
    Punt, Cornelis J. A.
    Douillard, Jean-Yves
    Hecht, J. Randolph
    Hurwitz, Herbert
    Diaz-Rubio, Eduardo
    Porschen, Rainer
    Tebbutt, Niall C.
    Fuchs, Charles S.
    Souglakos, John
    Falcone, Alfredo
    Sargent, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Prognostic factors for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC): Results from the French randomized phase II study TORAVA.
    Escudier, B. J.
    Negrier, S.
    Perol, D.
    Gravis, G.
    Delva, R.
    Bay, J.
    Geoffrois, L.
    Legouffe, E.
    Metzger, S.
    Ferlay, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] The Association Between Treatment (tx) Modifications Due to Adverse Events (AEs) and Overall Survival (OS) in Patients (pts) With Advanced Renal Cell Carcinoma (RCC) Treated With Sunitinib and Sorafenib: Results From a Multi-country Study in Europe
    Oudard, S.
    Porta, C.
    Castellano, D.
    McDermott, R.
    Nathan, P.
    McCaffrey, J.
    Neary, M. P.
    Korves, C.
    Suthoff, E. Dial
    Duh, M. S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S515 - S516
  • [46] Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents. Results from the GIM-13 AMBRA study
    Cazzaniga, Marina Elena
    De Placido, Sabino
    D'Alonzo, Alessia
    Piezzo, Michela
    Natoli, Clara
    Milani, Andrea
    Bologna, Alessandra
    Alu, Massimiliano
    Turletti, Anna
    Pugliese, Palma
    Biganzoli, Laura
    De Angelis, Claudia
    Garrone, Ornella
    Marchetti, Paolo
    Riccardi, Ferdinando
    Bernardo, Antonio
    Livi, Lorenzo
    Fabi, Alessandra
    Taverniti, Cristiana
    Romagnoli, Emanuela
    Pronzato, Paolo
    Mustacchi, Giorgio
    CANCER RESEARCH, 2020, 80 (04)
  • [47] Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study.
    Cazzaniga, Marina Elena
    Pronzato, Paolo
    Schettini, Francesco
    Del Mastro, Lucia
    Riemma, Maria
    Alu, Massimiliano
    Turletti, Anna
    Giordano, Monica
    Pugliese, Palma
    De Angelis, Claudia
    Garrone, Ornella
    Marchetti, Paolo
    Riccardi, Ferdinando
    Bernardo, Antonio
    Livi, Lorenzo
    Fabi, Alessandra
    Taverniti, Cristiana
    De Placido, Sabino
    Mustacchi, Giorgio
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Subgroup analyses of patients (pts) with advanced urothelial carcinoma (aUC) who had long-term progression-free survival (PFS) or overall survival (OS) with avelumab first-line maintenance (1LM) in the AVENANCE real-world study
    Barthelemy, P.
    Eymard, J-C.
    Flechon, A.
    Goupil, M. Gross
    Voog, E.
    Loriot, Y.
    Jaillon, C. Abraham
    Gobert, A.
    Chasseray, M.
    Kazan, E.
    Josse, C.
    Lambert, P.
    Paret, L.
    Thibault, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S1151 - S1152
  • [49] 813P Correlation of longitudinal target-lesions size with progression-free (PFS) and overall-survival (OS) in 2nd line metastatic renal cell carcinoma: a retrospective analysis of AXIS trial
    Lungayo, C. Luhata
    Fournier, L.
    Oudard, S.
    El Aidi, R. T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [50] Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance)
    Nixon, Andrew B.
    Halabi, Susan
    Shterev, Ivo
    Starr, Mark
    Brady, John C.
    Dutcher, Janice P.
    Hopkins, Judith O.
    Hurwitz, Herbert
    Small, Eric Jay
    Rini, Brian I.
    Febbo, Phillip G.
    George, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345